

RECORD SOURCE CATEGORIES:

Vital status information is obtained from Federal, State and local governments and other available sources selected from those listed in Appendix I. Information is obtained directly from the individual and employer records, whenever possible.

SYSTEMS EXEMPTED FROM CERTAIN PROVISIONS OF THE ACT:

None.

Appendix I—Potential Sources for Determination of Health Status, Vital Status and/or Last Known Address

Military records
 Appropriate State Motor Vehicle Registration Departments
 Appropriate State Driver's License Departments
 Appropriate State Government Division of: Assistance Payments (Welfare), Social Services, Medical Services, Food Stamp Program, Child Support, Board of Corrections, Aging, Indian Affairs, Worker's Compensation, Disability Insurance
 Retail Credit Association follow-up
 Veterans Administration files
 Appropriate employee union or association records
 Appropriate company pension or employment records
 Company group insurance records
 Appropriate State Vital Statistics Offices
 Life insurance companies
 Railroad Retirement Board
 Area nursing homes
 Area Indian Trading Posts
 Mailing List Correction Cards (U.S. Postal Service)
 Letters and telephone conversations with former employees of the same establishment as cohort member
 Appropriate local newspaper (obituaries)
 Social Security Administration
 Internal Revenue Service
 National Death Index
 Health Care Finance Administration
 Pension Benefit Guarantee Corporation
 State Disease Registries
 [FR Doc. 01-20478 Filed 8-14-01; 8:45 am]

BILLING CODE 4160-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration**

[Docket No. 01N-0287]

EVSCO Pharmaceuticals, an Affiliate of IGI, Inc.; Withdrawal of Approval of NADAs

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of two new animal drug

applications (NADAs) held by EVSCO Pharmaceuticals, an Affiliate of IGI, Inc. In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to remove the portions reflecting approval of the NADAs because these products are no longer manufactured or marketed.

DATES: Withdrawal of approval is effective August 27, 2001.

FOR FURTHER INFORMATION CONTACT:

Pamela K. Esposito, Center for Veterinary Medicine (HFV-210), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-5593.

SUPPLEMENTARY INFORMATION: EVSCO Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310, has requested that FDA withdraw approval of NADA 32-984 for Cerumite (chloramphenicol, prednisolone, tetracaine, and squalane) topical suspension, and NADA 55-005 for Liquichlor with Cerumene (squalane, pyrethrins, and piperonyl butoxide) topical suspension because the products are no longer manufactured or marketed.

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADAs 32-984 and 55-005 and all supplements and amendments are withdrawn effective August 27, 2001.

In a final rule published elsewhere in this issue of the **Federal Register**, the agency is amending the animal drug regulations to reflect the withdrawal of approval of these NADAs.

Dated: August 6, 2001.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 01-20574 Filed 8-14-01; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration**

[Docket No. 01D-0316]

Guidance on Inspections of Firms Producing Food Products Susceptible to Contamination With Allergenic Ingredients; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of an inspection guidance entitled "Guidance on Inspections of Firms Producing Food Products Susceptible to Contamination With Allergenic Ingredients." This guidance will assist FDA investigators and inspectors in evaluating conditions that may result in the introduction of undeclared allergens in foods.

DATES: Submit written or electronic comments on this guide at any time.

ADDRESSES: Submit written requests for single copies of the inspection guidance entitled "Guidance on Inspections of Firms Producing Food Products Susceptible to Contamination With Allergenic Ingredients" to the Director, Division of Emergency and Investigational Operations (HFC-130), Office of Regional Operations, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send two self-addressed adhesive labels to assist that office in processing your request, or fax your request to 301-443-6919. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guide.

Submit written comments concerning the guidance to the Dockets Management Branch (HFS-305), Food and Drug Administration, 5630 Fishers Lane, rm.1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>.

FOR FURTHER INFORMATION CONTACT:

Technical questions concerning food allergens: Kathy Gombas, Office of Field Programs (HFS-615), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-205-4231, FAX 202-260-0136.

Questions concerning regulatory procedures: Barbara Marcelletti, Office of Regional Operations (HFC-130), Office of Regulatory Affairs, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5635, FAX 301-443-6919.

SUPPLEMENTARY INFORMATION:**I. Background**

FDA has developed an inspection guidance identifying the following problem areas in the manufacture of foods that may result in undeclared food allergens: (1) Products that contain one or more allergenic ingredients, but the label does not declare the ingredient in the ingredient label; (2) products that become contaminated with an allergenic ingredient due to the firm's failure to exercise adequate control procedures; (3) products that are contaminated with